Q-omics provides the consensus-scored CCDC63 profile across patient tissues and cancer cell-line models. CCDC63 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CCDC63 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, CCDC63 RNA expression shows 7,208 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where CCDC63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC63 survival associations across molecular data types. CCDC63 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC63 RNA expression–survival associations across cancer types. High CCDC63 expression shows unfavorable associations in BLCA, KIRC, LGG and STAD, but favorable associations in UCS and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for CCDC63 RNA expression.
This table summarizes CCDC63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC63 shows lower tumor expression in KICH, HNSC and LUAD and higher tumor expression in COAD and BLCA. The KICH box plot shows higher CCDC63 RNA expression in normal versus tumor tissue (log2 FC = −0.059, t-test p = .002).
This table shows molecular features associated with CCDC63 in patient tissues and cancer cell lines. In patient samples, CCDC63 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
